Abbott Vaults Into Oral HCV Race; Near-Term Focus Is Humira, Split
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma did not offer much detail on plans to split into two publicly traded companies during its quarterly call, but did shed some light on its HCV pipeline one day ahead of EASL.
You may also be interested in...
Abbott Spin-Off AbbVie To Remain Close To Its Roots
Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.
The Abbott Split Up: Who Wins?
After implementing a workforce reduction of 1,900 U.S. employees in January, Abbott Laboratories Inc. in recent months had re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company, to retain the Abbott name, and a research-based pharmaceuticals company, which will take a new, to-be-determined name.